The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
CONCLUSIONS: Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20 years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine.PMID:38505696 | PMC:PMC10950408 | DOI:10.1155/2024/5877687 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Meaghan Roach Natalie Land Jennifer Hernandez Reina Rau Jacquelyn W Chou Stacey S Hickson Danielle F Rollmann J Ross Maclean Source Type: research
Near-infrared-guided Thoracoscopic Surgery and Future Near-infrared Targets
Vet Clin North Am Small Anim Pract. 2024 Mar 19:S0195-5616(24)00012-3. doi: 10.1016/j.cvsm.2024.02.011. Online ahead of print.ABSTRACTIntraoperative near-infrared fluorescence imaging allows for real time, noninvasive visualization of anatomic structures (blood vessels, lymphatic vessels) or diseased states (cancer, inflammation). This technique is easily adapted to thoracoscopy and has allowed for improved detection of lung tumors and other various cancers, thoracic lymphatics, and cardiothoracic vasculature.PMID:38508966 | DOI:10.1016/j.cvsm.2024.02.011 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Chris Thomson Source Type: research
Significance of ZO-1, an Intercellular Adhesion Molecule, as a Prognostic Marker in Lung Adenocarcinoma
Tokai J Exp Clin Med. 2024 Apr 20;49(1):1-8.ABSTRACTIn epithelial tissues, intercellular adhesion structures are formed between adjacent cells via intercellular adhesion factors, such as zonula occludens (ZO-1), to maintain the structure and function of tissues and organs, thereby contributing to homeostasis. Epithelial cells are polarized into apical and basal regions by tight junctions (TJs), a type of intercellular adhesion structure, and thus, their intracellular organelles are asymmetrically distributed. Normal epithelial cells maintain their cellular function by controlling cytoskeletal reorganization, motility, and ...
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Takaaki Tsuboi Tomohiko Matsuzaki Susumu Takekoshi Kei Nakano Kie Shioyama Tomoki Higeta Kazuhiro Matsuo Takashi Ishihara Masaya Ohara Kenei Nakazato Ryota Masuda Masayuki Iwazaki Source Type: research
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
CONCLUSIONS: Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20 years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine.PMID:38505696 | PMC:PMC10950408 | DOI:10.1155/2024/5877687 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Meaghan Roach Natalie Land Jennifer Hernandez Reina Rau Jacquelyn W Chou Stacey S Hickson Danielle F Rollmann J Ross Maclean Source Type: research
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
CONCLUSION: Combined IBC treatment achieved superior DCR and PFS compared with IC or BC in patients with PD-L1-negative metastatic lung adenocarcinoma, while did not increase the adverse events.PMID:38499838 | DOI:10.1007/s00432-024-05637-1 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Yihui Ge Yujing Zhan Jie He Juan Li Jian Wang Xiaojuan Wei Chunni Wang Aiqin Gao Yuping Sun Source Type: research
Validation of an Updated Algorithm to Identify Patients With Incident Non-Small Cell Lung Cancer in Administrative Claims Databases
CONCLUSION: An updated treatment-based algorithm identifying patients with incident NSCLC was validated using EHR data and distinguished lung cancer subtypes in claims databases when EHR data were not available.PMID:38502111 | DOI:10.1200/CCI.23.00165 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Sandip Pravin Patel Rongrong Wang Summera Qiheng Zhou Daniel Sheinson Ann Johnson Janet Shin Lee Source Type: research
Circulating serum exosomes i-tRF-AspGTC and tRF-1-SerCGA as diagnostic indicators for non-small cell lung cancer
CONCLUSION: The expression of serum exosomes i-tRF-AspGTC and tRF-1-SerCGA was significantly downregulated in NSCLC patients. These exosomes could be used as predictive indicators for diagnosis or early diagnosis of NSCLC.PMID:38502292 | DOI:10.1007/s12094-024-03423-6 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Jiefei Peng Yue Zhang Guangfei Zhou Luolin Shao Lin Li Zhijun Zhang Source Type: research
Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment
CONCLUSIONS: Our findings suggest that the timing of SM diagnosis (synchronous versus metachronous) does not significantly affect survival outcomes following neurosurgical treatment for SM. These results support the consideration of neurosurgical procedures regardless of the temporal pattern of SM manifestation.PMID:38502313 | DOI:10.1007/s00432-024-05657-x (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Mohammed Banat Anna-Laura Potthoff Motaz Hamed Valeri Borger Jasmin E Scorzin Tim Lampmann Harun Asoglu Logman Khalafov Frederic C Schmeel Daniel Paech Alexander Radbruch Louisa Nitsch Johannes Weller Ulrich Herrlinger Marieta Toma Gerrit H Gielen Hartmut Source Type: research
Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study
CONCLUSION: Durvalumab demonstrated similar outcomes in elderly compared to younger patients. However, AEs were more common in elderly patients. Thus, judicious selection of patients and chemotherapy regimens, coupled with careful AE monitoring, are important factors for ensuring optimal durvalumab treatment.PMID:38503590 | DOI:10.1016/j.cllc.2024.02.006 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Ji Eun Park Kyung Soo Hong Sun Ha Choi Shin Yup Lee Kyeong-Cheol Shin Jong Geol Jang Yong Shik Kwon Sun Hyo Park Keum-Ju Choi Chi Young Jung Jung Seop Eom Saerom Kim Hee Yun Seol Jehun Kim Insu Kim Jin Han Park Tae Hoon Kim June Hong Ahn Source Type: research
Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation
CONCLUSION: This is the first case showing the absence of cross-toxicity between 1b MET inhibitors.PMID:38494868 | DOI:10.1080/17843286.2024.2330137 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ariane Vanderick Beno ît Colinet Source Type: research
Lung Cancer Screening: An Opportunity to Promote Physical Activity?
JTO Clin Res Rep. 2024 Feb 20;5(3):100651. doi: 10.1016/j.jtocrr.2024.100651. eCollection 2024 Mar.NO ABSTRACTPMID:38496375 | PMC:PMC10940996 | DOI:10.1016/j.jtocrr.2024.100651 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Alice Avancini Lorenzo Belluomini Morten Quist Sara Pilotto Source Type: research
The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
CONCLUSIONS: Increased use of IO was associated with a change in treatment patterns and improved survival for patients with stage IIIA(N2) NSCLC.PMID:38496376 | PMC:PMC10941003 | DOI:10.1016/j.jtocrr.2024.100654 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Lye-Yeng Wong Douglas Z Liou Mohana Roy Irmina A Elliott Leah M Backhus Natalie S Lui Joseph B Shrager Mark F Berry Source Type: research
Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study
CONCLUSIONS: Patients with metastatic lung cancer with Medicaid coverage were found to have exceedingly low biomarker testing rates; only 57% had evidence of any biomarker testing. Although no consistent differences between Black and White races were identified, this study calls attention to care experienced by socioeconomically disadvantaged patients with metastatic lung cancer in the United States.PMID:38496377 | PMC:PMC10941001 | DOI:10.1016/j.jtocrr.2024.100643 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Debora S Bruno Xiaohong Li Lisa M Hess Source Type: research
SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report
Clin Respir J. 2024 Mar;18(3):e13740. doi: 10.1111/crj.13740.ABSTRACTLambert-Eaton myasthenic syndrome (LEMS) is a rare paraneoplastic neurological syndrome of the neuromuscular transmission. The symptoms often progress slowly and can be misdiagnosed in early stage. Seropositive SOX-1 antibodies are support for the diagnosis of LEMS and have high specificity for small cell lung cancer (SCLC). In this paper, we report a case of a 56-year-old man with smoking history who was admitted to hospital with progressive muscle weakness of the proximal legs. LEMS was diagnosed by repetitive nerve stimulation (RNS) testing and seropos...
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Liming Zhao Hongyan He Weixin Han Yizhe Meng Lifei Kang Yanqiang Chen Source Type: research
Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation
CONCLUSION: This is the first case showing the absence of cross-toxicity between 1b MET inhibitors.PMID:38494868 | DOI:10.1080/17843286.2024.2330137 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Ariane Vanderick Beno ît Colinet Source Type: research
